Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Midatech ups sales hopes; brain cancer treatment chosen for human trials

The firm also updated the market on its financial progress
Midatech ups sales hopes; brain cancer treatment chosen for human trials
The Bristol Royal Infirmary has chosen Midatech’s glioblastoma treatment

--- ADDS BROKER COMMENT AND UPDATED SHARE PRICE ---

Fast growing drug delivery group Midatech’s (LON:MTPH, NASDAQ:MTP)  pleased the market with an upgraded revenue forecast, as its paediatric brain tumour treatment was chosen for a programme by the Bristol Royal Infirmary.

The hospital has chosen Midatech’s glioblastoma treatment for its compassionate use programme to deliver an active therapeutic agent to a rare paediatric brain tumour.

Panmure Gordon said: “It signifies what we consider to represent a potential acceleration of the company’s programmes in brain cancer, notably in young children."

These highly aggressive and difficult-to-treat tumours are found at the base of the brain and occur almost exclusively in children.

“While this is a single programme for a rare disease it brings forward the in-human trials of the Midatech cancer therapeutic products very significantly,” the company said.

Panmure added: “We consider this a strong validation of Midatech’s platform and, if successful, could result in a fasttracked product to market where there is currently an unmet clinical need."

The firm also updated the market on its financial progress, which, as a result of recent acquisitions of oncology specialists DARA Biosciences and Zuplenz, shows sales will be ahead of market hopes.

Panmure Gordon said the news “helps to reaffirm our view on trading,” as it upped its full-year revenue expectations to £1.3mln from £1.2mln.

“In light of the confident trading update, the accelerated in-human application of the company’s technology in oncology and the, in our view, unjustified current share-price levels, we regard Midatech as a compelling investment,” the broker added.

Shares in the firm rocketed by lunch, up 15% to 205p.

View full MTPH profile View Profile

Midatech Pharma Plc Timeline

Related Articles

woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half
researcher using microscope
September 28 2017
A total of £6mln is expected to come via a share placing and up to a further £2mln through an open offer of stock to existing investors

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use